Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 501Carcinoma, Renal Cell 165Urinary Bladder Neoplasms 135Carcinoma, Transitional Cell 71Carcinoma, Non-Small-Cell Lung 57Kidney Neoplasms 56Melanoma 53Breast Neoplasms 51Ovarian Neoplasms 43Neoplasms 41Neoplasm Metastasis 40Colorectal Neoplasms 38Lung Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Sarcoma 24Endometrial Neoplasms 24Triple Negative Breast Neoplasms 21Pancreatic Neoplasms 19Esophageal Neoplasms 18Carcinoma, Hepatocellular 17Wilms Tumor 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Urologic Neoplasms 14Colonic Neoplasms 14Urethral Neoplasms 13Ureteral Neoplasms 13

Interventions

gallium Ga 68 dotatate 1gallium 68 PSMA-11 1copper dotatate CU-64 1Metoclopramide 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Gallium 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Neuroendocrine Prostate Cancer × Genitourinary × Clear all
NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡